The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer.
Adjuvant treatment
Colon cancer
Duration of treatment
MSI testing
Microsatellite instability
Journal
Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
accepted:
19
10
2020
pubmed:
8
11
2020
medline:
26
3
2022
entrez:
7
11
2020
Statut:
ppublish
Résumé
Although several clinical factors which show the benefit of adjuvant chemotherapy (AC) in early-stage colon cancer use for evaluating the risk of relapse, there is no consensus on which risk factors are more reliable. In this study, we evaluated both the utility of MSI and the daily practice of the Turkish oncologists in stage II and III colon cancer. We conducted an online questionnaire which was consisting of twenty questions including the treatment choices and duration about stage II-III colon cancer depending on sidedness and risk factors for relapse. More than 65% of the oncologists declared the use of MSI testing in stage II colon cancer without considering any risk factors. In stage 3 colon cancer oncologists had an equal decision "to do or not to do" in MSI testing. More than 50% of the oncologists had preferred XELOX protocol in high-risk stage II (T4N0) colon cancer, while three out of four preferred observation in low-risk stage II (T3N0) patients without risk factors. Two-thirds of the oncologists had preferred 6 months of treatment in stage II colon cancer with at least one risk factor. Turkish oncologists participating to this trial had declared conflicting results about adjuvant treatment in early-stage colorectal cancer in their daily practice compared with the updated guidelines, especially, MSI evaluation utility in stage III colon cancers, adjuvant chemotherapy (AC) duration, and oxaliplatin adding to AC in elderly and stage II patients.
Identifiants
pubmed: 33159235
doi: 10.1007/s12029-020-00542-5
pii: 10.1007/s12029-020-00542-5
doi:
Substances chimiques
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
57-63Informations de copyright
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the cancer care Ontario program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol 2004;22(16):3395–407. https://doi.org/10.1200/JCO.2004.03.087 .
Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22:1797–806.
doi: 10.1200/JCO.2004.09.059
Schmoll HJ, Tabernero J, Maroun J, De Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol [Internet]. 2015/08/31. United States; 2015;33:3733–40. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26324362
André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16.
doi: 10.1200/JCO.2008.20.6771
Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol [Internet]. 2007/04/30. United States; 2007;25:2198–204. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17470851
Bergquist JR, Thiels CA, Spindler BA, Shubert CR, Hayman AV, Kelley SR, et al. Benefit of Postresection Adjuvant Chemotherapy for Stage III Colon Cancer in Octogenarians: Analysis of the National Cancer Database. Dis Colon Rectum. 2016;59:1142–9.
doi: 10.1097/DCR.0000000000000699
Twelves C, Wong A, Nowacki MP, Abt M, Burris H, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696–704.
doi: 10.1056/NEJMoa043116
Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787–93.
doi: 10.1038/ng1834
Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping coloreetal tumors. J Clin Oncol. 2002;20:1043–8.
doi: 10.1200/JCO.2002.20.4.1043
SEER. Cancer stat facts: Colon and rectum cancer. [Internet]. SEER Cancer Stat Facts Color. Cancer. 2019. p. 2. Available from: https://seer.cancer.gov/statfacts/html/colorect.html .
Sinclair AH, Schymura MJ, Boscoe FP, Yung RL, Chen K, Roohan P, et al. Measuring colorectal cancer care quality for the publicly insured in New York State. Cancer Med. 2012;1:363–71.
doi: 10.1002/cam4.30
Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney MM. Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol. 2006;101:2308–18.
doi: 10.1111/j.1572-0241.2006.00775.x
Sanders T, Skevington S. Do bowel cancer patients participate in treatment decision-making? Findings from a qualitative study. Eur J Cancer Care (Engl). 2003;12:166–75.
doi: 10.1046/j.1365-2354.2003.00370.x
Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004.22(16):3408–19. https://doi.org/10.1200/JCO.2004.05.063 .
Kumar A, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Woods R, et al. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer. 2015;121:527–34.
doi: 10.1002/cncr.29072
Kannarkatt J, Joseph J, Kurniali PC, Al-Janadi A, Hrinczenko B. Adjuvant chemotherapy for stage II colon cancer: A clinical dilemma. J Oncol Pract. 2017;13:233–41.
doi: 10.1200/JOP.2016.017210
Benson AB, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, et al. Colon cancer, version 1.2017: Clinical practice guidelines in oncology. JNCCN J Natl Compr Cancer Netw 2017. p. 370–98.
Schofield PE, Butow PN, Thompson JF, Tattersall MHN, Beeney LJ, Dunn SM. Psychological responses of patients receiving a diagnosis of cancer. Ann Oncol. 2003;14:48–56.
doi: 10.1093/annonc/mdg010
Mulders M, Vingerhoets A, Breed W. The impact of cancer and chemotherapy: Perceptual similarities and differences between cancer patients, nurses and physicians. Eur J Oncol Nurs. 2008;12:97–102.
doi: 10.1016/j.ejon.2007.10.002
Sinicrope FA, Rego RL, Halling KC, Foster N, Sargent DJ, La Plant B, et al. Prognostic Impact of Microsatellite Instability and DNA Ploidy in Human Colon Carcinoma Patients. Gastroenterology. 2006;131:729–37.
doi: 10.1053/j.gastro.2006.06.005
Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.
doi: 10.1056/NEJMoa022289
Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28:466–74.
doi: 10.1200/JCO.2009.23.3452
Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst. 2012;104:1635–46.
doi: 10.1093/jnci/djs427
Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet 2012; 151–7.
Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant tre. J Clin Oncol. 2012;30:3353–60.
doi: 10.1200/JCO.2012.42.5645
Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer. JAMA Oncol [Internet]. cy;3:194. Available from: http://oncology.jamanetwork.com/article.aspx?doi = 10.1001/jamaoncol.2016.3797
Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3(2):211–219. https://doi.org/10.1001/jamaoncol.2016.4227 .
Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378:1177–88.
doi: 10.1056/NEJMoa1713709
Taieb J, Taly V, Vernerey D, Bourreau C, Bennouna J, Faroux R, et al. Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration. Ann Oncol. 2019;30:v867.
doi: 10.1093/annonc/mdz394.019
Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med [Internet]. 2016;8:346ra92-346ra92. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27384348